Related Experiment Video
Updated: Jun 20, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Immune checkpoint inhibitor-related myocarditis in a patient with hepatocellular carcinoma: a case report
Yuqiang Zhou1, Zhiliang Zhang1, Shasha Liu2
1The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Abstract:
Immune checkpoint inhibitors (ICIs) are pivotal in treating advanced malignancies, including hepatocellular carcinoma (HCC). However, they can trigger immune-related adverse events (irAEs), among which myocarditis is one of the most life-threatening. Herein, we report the case of a 56-year-old man with HCC who developed myocarditis after receiving two cycles of the PD-1 inhibitor sintilimab. The diagnosis was established via cardiac magnetic resonance (CMR) and confirmed by endomyocardial biopsy (EMB). Following treatment with high-dose corticosteroids and supportive therapy, the patient's condition exhibited significant improvement.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Myocarditis I: Introduction
